Results 281 to 290 of about 126,758 (293)

Cd19(Cd0.2Ni0.8)5

2006
P. Villars, K. Cenzual, J. Daams, R. Gladyshevskii, O. Shcherban, V. Dubenskyy, N. Melnichenko-Koblyuk, O. Pavlyuk, S. Stoiko, L. Sysa   +9 more
openaire   +1 more source

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Journal of Cellular and Molecular Medicine, 2016
Annette Romanski, Gesine Bug, Erhard Seifried   +2 more
exaly  

CD19 (16p11.2)

2008
openaire   +1 more source

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas

Molecular Therapy, 2018
CARLOS A Ramos, Rayne H Rouce, Birju Mehta   +2 more
exaly  

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Molecular Therapy - Methods and Clinical Development, 2019
Maria Castella, Anna Boronat, Raquel Martín-Ibáñez   +2 more
exaly  

MAb CLB-CD19

Inpharma Weekly, 1991
openaire   +1 more source

Anti-CD19 Immunotoxins

2020
openaire   +1 more source

CD19 as an attractive target for antibody-based therapy

MAbs, 2012
exaly  

CD19 wt Allele

2020
openaire   +1 more source

CD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients

Case Medical Research, 2019
openaire   +1 more source